Amgen 2001 Annual Report Download - page 26

Download and view the complete annual report

Please find page 26 of the 2001 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 54

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54

24
Amgen Products and Product Candidates
Products/Product Development Phase
Therapeutic Areas Candidates Phase 1 Phase 2 Phase 3 Filed Approved
Nephrology
Anemia EPOGEN
®
(Epoetin alfa) ●●●●●
Anemia Aranesp
™
(darbepoetin alfa) ●●●●●
Secondary hyperparathyroidism Calcimimetics Program ●●●
Hematology & Oncology
Neutropenia NEUPOGEN
®
(Filgrastim) ●●●●●
PBPC mobilization NEUPOGEN
®
●●●●●
PBPC mobilization STEMGEN
®
(Ancestim) ●●●●●
(1)
Neutropenia Neulasta
™
(pegfilgrastim) ●●●●●
(2)
Anemia Aranesp
™
●●●●
Non-Hodgkin’s
lymphoma Epratuzumab ●●●
Mucositis KGF
(3)
●●●
Aplastic anemia STEMGEN
®
●●
Bone Metastases Osteoprotegerin Program ●●
Bone & Inflammation
Rheumatoid Arthritis Kineret
™
(anakinra) ●●●●●
(2)
Rheumatoid Arthritis PEG-sTNF-RI
(4)
●●
Osteoporosis Osteoprotegerin Program ●●
Neurology & Endocrinology
Primary hyperparathyroidism Calcimimetics Program ●●
Lipodystrophy Leptin Program ●●
Phase 1 Clinical Trial
Investigate safety and proper dose ranges of a product candidate in a small number of human subjects.
Phase 2 Clinical Trial
Investigate side effect profiles and efficacy of a product candidate in a larger number of patients who have the disease or condition
under study.
Phase 3 Clinical Trial
Investigate safety and efficacy of product candidate in a large number of patients who have the disease or condition under study.
(1)
Approved in Australia, Canada, and New Zealand only
(2)
Approved in United States only
(3)
Keratinocyte growth factor
(4)
PEGylated soluble tumor necrosis factor-type 1 receptor